{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:10:53Z","timestamp":1790687453098,"version":"4.1.0"},"reference-count":47,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T00:00:00Z","timestamp":1180828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The pathophysiologic basis for multiple myeloma (MM) has been attributed to the dysregulation of various paracrine or autocrine growth factor loops and to perturbations in several signal transduction pathways including I<jats:italic>\u03ba<\/jats:italic>B kinase\/nuclear factor\u2010<jats:italic>\u03ba<\/jats:italic>B (IKK\/NF\u2010<jats:italic>\u03ba<\/jats:italic>B). The present study aimed at investigating the effect of a pharmaceutical IKK2 inhibitor, the anilinopyrimidine derivative AS602868, on the <jats:italic>in vitro<\/jats:italic> growth of 14 human MM cell lines (HMCL) and primary cells from 13 patients. AS602868 induced a clear dose\u2010dependent inhibition of MM cell growth on both HMCL and primary MM cells, which was the result of a simultaneous induction of apoptosis and inhibition of the cell cycle progression. Combination of AS602868 with suboptimal doses of melphalan or Velcade showed an additive effect in growth inhibition of HMCL. AS602868 also induced apoptosis of primary myeloma cells. Importantly, AS602868 did not alter the survival of other bone marrow mononuclear cells (CD138<jats:sup>\u2212<\/jats:sup>) co\u2010cultured with primary MM (CD138<jats:sup>+<\/jats:sup>) cells, except for CD34<jats:sup>+<\/jats:sup> haematopoietic stem cells. The results demonstrate the important role of NF\u2010<jats:italic>\u03ba<\/jats:italic>B in maintaining the survival of MM cells and suggest that a pharmacological inhibition of the NF\u2010<jats:italic>\u03ba<\/jats:italic>B pathway by the IKK2 inhibitor AS602868 can efficiently kill HMCL and primary myeloma cells and therefore might represent an innovative approach for treating MM patients.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2007.06629.x","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T07:05:59Z","timestamp":1180854359000},"page":"160-168","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Targeting NF\u2010<i>\u03ba<\/i>B pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth"],"prefix":"10.1111","volume":"138","author":[{"given":"Michel","family":"Jourdan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Moreaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John De","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kar\u00e8ne","family":"Mahtouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Abouladze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Baudard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"R\u00e8me","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Fran\u00e7ois","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Dreano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,6,3]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90036-3"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1320"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2151"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3756"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80011-4"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(99)90160-0"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02127.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2006.00362.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402875"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0305855101"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.9.3044"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2000.02364.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.4049\/jimmunol.161.6.2692","article-title":"IFN\u2010alpha is a survival factor for human myeloma cells and reduces dexamethasone\u2010induced apoptosis","volume":"161","author":"Ferlin\u2010Bezombes M.","year":"1998","journal-title":"Journal of Immunology"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2876"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206963"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1463"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830271232"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403269"},{"key":"e_1_2_6_21_1","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood.V88.10.3972.bloodjournal88103972","article-title":"Interleukin\u201010 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop","volume":"88","author":"Gu Z.J.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401632"},{"key":"e_1_2_6_23_1","first-page":"3071","article-title":"The proteasome inhibitor PS\u2010341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima T.","year":"2001","journal-title":"Cancer Research"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M200360200"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2501"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01510.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.9.2853"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00623.x"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4400758"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni0302-221"},{"key":"e_1_2_6_31_1","first-page":"1136","article-title":"The proteasome inhibitor PS\u2010341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents","volume":"9","author":"Ma M.H.","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1510"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208536"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209699"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.11.4079"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4525"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1984"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4512"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03102.x"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3531"},{"key":"e_1_2_6_41_1","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1182\/blood.V91.12.4727","article-title":"A gp130 interleukin\u20106 transducer\u2010dependent SCID model of human multiple myeloma","volume":"91","author":"Rebouissou C.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1936"},{"key":"e_1_2_6_43_1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4049\/jimmunol.163.1.514","article-title":"Induced expression of B7\u20101 on myeloma cells following retroviral gene transfer results in tumor\u2010specific recognition by cytotoxic T cells","volume":"163","author":"Tarte K.","year":"1999","journal-title":"Journal of Immunology"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(95)00072-I"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2004.11.009"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/7410"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920315)69:6<1373::AID-CNCR2820690612>3.0.CO;2-1"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.12.3654.3654"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2007.06629.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2007.06629.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T07:25:18Z","timestamp":1697441118000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2007.06629.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,3]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["10.1111\/j.1365-2141.2007.06629.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06629.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,3]]},"assertion":[{"value":"2007-06-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}